Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Illumina, Inc.NASDAQ: ILMN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $252M rose 3.7% year over year, ahead of the -3.4% change in trailing-twelve-month research & development. Sequentially, it rose 5.0% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.
Context
- Research & development amounted to 21.9% of revenue in FY2025, down 4.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3.7% holds above the trailing-twelve-month pace of -3.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 951M USD
- Year-over-year change
- -18.6%
- 4-year CAGR
- -5.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 951M | -18.6% |
| FY2024 | 2024-12-29 | 1.17B | -13.7% |
| FY2023 | 2023-12-31 | 1.35B | +2.5% |
| FY2022 | 2023-01-01 | 1.32B | +11.5% |
| FY2021 | 2022-01-02 | 1.19B | — |
Research & Development vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 research & development of $958M is the highest of the 11 companies compared; the peer median is $85.59M.
- Its year-over-year change of -3.4% is the 8th highest of 11, against a peer median of +7.3%.
- Research & development amounts to 21.3% of revenue for ILMN, versus a peer median of 29.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $958M | -3.4% | -10.4% | 21.3% | |
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Sep 2026 | $222.54M | -10.9% | -3.5% | 36.0% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $83.32M | +64.3% | -5.8% | 18.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $35.89M | +5.3% | -1.7% | 44.2% | |
| Peer median (excluding ILMN) | $85.59M | +7.3% | -1.7% | 29.7% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.